2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 132

Novel Therapeutic Peptides Which Target CD206 Inhibit Macrophage Dependent Fibroblast Activation in Scleroderma
Abstract Number: 2098

NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus
Abstract Number: 977

Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Abstract Number: 2331

Obesity Might Positively Affect TNF Mediated Bone Metabolism in RA Patients
Abstract Number: 969

Obstetric Outcomes in Women with Psoriatic Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 2434

Obstetric Outcomes in Women with Takayasu Arteritis: Results from Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 424

Occult Extractable Synovial Fluid in Inflammatory and Non-Inflammatory Arthritis of the Knee
Abstract Number: 201

Occupational Exposure to Coal and Silica Dust Is Associated with Elevated Risk of Rheumatoid Arthritis in Coal Mining Areas of US
Abstract Number: 1767

Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Abstract Number: 2267

Ocular and Systemic Features in 262 Patients with Systemic Sarcoidosis and Its Correlation with Iwos Criteria
Abstract Number: 1491

Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis
Abstract Number: 461

Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Abstract Number: 2062

Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study
Abstract Number: 2824

On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering
Abstract Number: 427

One Year Efficacy and Safety of One or Three Injections of Hylan G-F 20 for Knee Osteoarthritis: A Systematic Literature Review and Meta-Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].